C M Bidwell & Associates LTD Blueprint Medicines Corp Transaction History
C M Bidwell & Associates LTD
- $162 Million
- Q3 2024
A detailed history of C M Bidwell & Associates LTD transactions in Blueprint Medicines Corp stock. As of the latest transaction made, C M Bidwell & Associates LTD holds 827 shares of BPMC stock, worth $79,102. This represents 0.05% of its overall portfolio holdings.
Number of Shares
827
Previous 378
118.78%
Holding current value
$79,102
Previous $40,000
90.0%
% of portfolio
0.05%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding BPMC
# of Institutions
349Shares Held
60.2MCall Options Held
1.05MPut Options Held
616K-
Vanguard Group Inc Valley Forge, PA6.68MShares$639 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$636 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$515 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$379 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$265 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.71B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...